SaaS Company's Remote Patient Monitoring Solutions Help Health Care Professionals Enhance Chronic Disease Management
MELVILLE, N.Y., November 15, 2022 - Henry Schein Medical, the U.S. medical business of Henry Schein, Inc., today announced the expansion of its SolutionsHub with Rimidi, a SaaS company that brings together remote patient monitoring tools, patient reported outcomes, and clinical decision support to help clinicians enhance patient care. As a result of this new distribution agreement, Henry Schein will offer its clinic, medical group, and health system customers access to Rimidi's cloud-based software platform. As a result, this relationship will help further expand efforts to deliver to these health care providers an efficient model of care for patients with chronic conditions.
Integrated with a broad range of connected medical devices, including cellular and Bluetooth-enabled blood-glucose meters, scales, blood pressure cuffs, pulse-oximeters, insulin dosing pens, and continuous glucose monitors, Rimidi's software platform facilitates remote patient monitoring (RPM), patient reported outcomes, and clinical decision support into the clinical workflow. This allows for data aggregation across multiple devices into a single, streamlined solution that integrates with the clinician's Electronic Health Record (EHR) and offers time effective and robust data-informed clinical decision support.
"At Henry Schein, we recognize the ever-growing rates of chronic disease and remain committed to helping our customers on their continual journey to provide proactive care," said Michael Casamassa, Vice President, Solutions and Planning, Henry Schein Medical. "By working with Rimidi, we can bring patient monitoring solutions into the existing workflow so that health care professionals can actively engage patients and further optimize disease management in between visits."
Physician-founded and led, Rimidi is designed to support health care providers with their quality improvement, patient engagement, and workflow optimization objectives. Current clinical use cases of the Rimidi platform include chronic, cardiometabolic conditions, epidemic management, and perioperative care.
"At Rimidi, our sweet spot is the intersection of clinical and technical innovation," said Lucienne Ide, MD, PhD, Founder and CEO of Rimidi. "From the clinical perspective, it's important to remember that the goal of RPM isn't just monitoring - it's management. To do that effectively, remote patient monitoring data needs to be transmitted, merged with other patient data, analyzed, and interpreted in a way that is efficient and meaningful to clinicians. That's how we have built Rimidi."
To learn more about Rimidi and to explore Henry Schein Medical's full portfolio of solutions, please visit the Henry Schein SolutionsHub at.
About Henry Schein, Inc.
Henry Schein, Inc. (Nasdaq: HSIC) is a solutions company for health care professionals powered by a network of people and technology. With approximately 22,000 Team Schein Members worldwide, the Company's network of trusted advisors provides more than 1 million customers globally with more than 300 valued solutions that help improve operational success and clinical outcomes. Our Business, Clinical, Technology, and Supply Chain solutions help office-based dental and medical practitioners work more efficiently so they can provide quality care more effectively. These solutions also support dental laboratories, government and institutional health care clinics, as well as other alternate care sites.
Henry Schein operates through a centralized and automated distribution network, with a selection of more than 120,000 branded products and Henry Schein private-brand products in stock, as well as more than 180,000 additional products available as special-order items. A FORTUNE 500 Company and a member of the S&P 500® index, Henry Schein is headquartered in Melville, N.Y., and has operations or affiliates in 32 countries and territories. The Company's sales reached $12.4 billion in 2021, and have grown at a compound annual rate of approximately 12.5 percent since Henry Schein became a public company in 1995.
For more information, visit Henry Schein at www.henryschein.com, Facebook.com/HenrySchein, Instagram.com/HenrySchein, and Twitter.com/HenrySchein.
Ann Marie Gothard, Vice President, Corporate Media Relations, Annmarie.email@example.com, (631) 390-8169
Henry Schein Inc. published this content on 15 November 2022 and is solely responsible for the information contained therein. Distributed by, unedited and unaltered, on 15 November 2022 19:21:01 UTC.